ERCC2 and non-small cell lung carcinoma: Likewise, the presence of ERCC2 rs13181 and XRCC3 rs861539 SNPs is significantly associated with treatment-related outcomes, including progression-free and overall survival for ERCC2 and objective response rate for XRCC3, respectively, in non-small cell lung cancer patients receiving platinum-based regimens [20].